Dr. Baltimore Says It's Time to Revive AIDS Vaccine Ideas

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

BETHESDA, Md--It's time to recycle some old ideas in AIDS vaccines, Nobel laureate David Baltimore, PhD, told the Advisory Committee to the Director of the National Institutes of Health.

BETHESDA, Md--It's time to recycle some old ideas in AIDS vaccines,Nobel laureate David Baltimore, PhD, told the Advisory Committee to theDirector of the National Institutes of Health.

Dr. Baltimore, currently at the Massachusetts Institute of Technologyand president-elect of the California Institute of Technology, chairs anadvisory committee named by NIH director Harold Varmus, MD, to devise acomprehensive national research program to develop an effective AIDS vaccine.Looking at the candidate AIDS vaccines tested so far, Dr. Baltimore expressedhis concern that none of them may be able to effectively prevent the disease.

The growing understanding of how the human immunodeficiency virus changesand functions has led him to conclude that scientists need to reconsidera variety of vaccine approaches discarded earlier, he said. These includekilled viruses, virus-like particles, protein-based vaccines, naked DNA,and live, attenuated vaccines.

Because a live vaccine would involve actually infecting people, albeitwith a crippled virus, "that concept is appropriately worrisome,"Dr. Baltimore acknowledged. Nonetheless, that approach could be the mosteffective.

"What the committee is doing is trying to suggest new scientificinitiatives," he said. "What we'd most like to do is get newvaccine concepts under testing." However, he emphasized that an AIDSvaccine will take years to perfect: "It is intrinsic to the developmentthat it takes a long time."

Dr. Baltimore said the AIDS vaccine committee has held a series of regionalworkshops intended to generate new ideas and bring new minds into the effort."We would like to encourage people who have not worked on HIV to comeinto the field," he said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content